Scandinavian ChemoTech AB Series B (CMOTEC-B) — Cash Flow-to-Debt Ratio
Scandinavian ChemoTech AB Series B (CMOTEC-B) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of Skr-1.14 Million could theoretically repay 0% of its total liabilities (Skr9.47 Million) in one year. Check cash flow reinvestment rate of Scandinavian ChemoTech AB Series B to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Scandinavian ChemoTech AB Series B Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Scandinavian ChemoTech AB Series B across 12 annual periods. Also explore CMOTEC-B total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Scandinavian ChemoTech AB Series B (2014–2025)
Year-by-year debt coverage analysis for Scandinavian ChemoTech AB Series B. For market capitalisation and broader financial context, see Scandinavian ChemoTech AB Series B stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.37x | Skr-3.75 Million | Skr10.01 Million | ▲ +78.9% |
| 2024 | -1.78x | Skr-13.14 Million | Skr7.40 Million | ▲ +62.6% |
| 2023 | -4.75x | Skr-18.23 Million | Skr3.84 Million | ▼ -86.5% |
| 2022 | -2.55x | Skr-19.63 Million | Skr7.71 Million | ▲ +74.9% |
| 2021 | -10.13x | Skr-19.18 Million | Skr1.89 Million | ▼ -705.9% |
| 2020 | -1.26x | Skr-8.49 Million | Skr6.75 Million | ▲ +13.1% |
| 2019 | -1.45x | Skr-11.23 Million | Skr7.76 Million | ▲ +26.9% |
| 2018 | -1.98x | Skr-4.58 Million | Skr2.31 Million | ▲ +66.2% |
| 2017 | -5.86x | Skr-14.97 Million | Skr2.56 Million | ▼ -74.8% |
| 2016 | -3.35x | Skr-7.52 Million | Skr2.24 Million | ▼ -3979.6% |
| 2015 | -0.08x | Skr-474.99K | Skr5.78 Million | ▲ +96.1% |
| 2014 | -2.08x | Skr-40.91K | Skr19.63K | — |